Filing Flows › Entrada Therapeutics (TRDA) › Q2 2026
Entrada Therapeutics (TRDA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Entrada Therapeutics (TRDA) reported revenue of $898K for the second quarter 2026 (Q2 2026), -54% from a year earlier and +3% from the quarter before.
Entrada Therapeutics, Q2 2026: revenue $898K (-54% year over year), net loss $42.8M, operating cash flow −$32.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $898K | +3% | -54% |
| Operating profit | −$45.0M | — | — |
| Net earnings | −$42.8M | — | — |
| Operating cash flow | −$32.5M | — | — |
What changed
Revenue was $898K in Q2 2026, down 54% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $45.0M, an operating margin of -5007.0%. Total costs fell 6% while revenue fell 54%. The quarter ended with a net loss of $42.8M, wider than the previous quarter's $39.7M loss.
Operating cash flow was −$32.5M. Non-cash charges added back $800K of depreciation and $5.2M of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $11K exceeded it, leaving free cash flow of −$32.5M.
Questions
What was Entrada Therapeutics' revenue in the second quarter 2026?
Entrada Therapeutics (TRDA) reported revenue of $898K for the second quarter 2026 (Q2 2026), -54% from a year earlier and +3% from the quarter before.